Hospital
Multicare Health System
Multicare Health System was paid $77.99M by Medicaid between Jan 2018 and Dec 2024, across 426 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoMULTICARE HEALTH SYSTEM
PUYALLUP, WA 98372
PUYALLUP, WA 98372
33aNPI1841231461assigned 06/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$77.99M
24GClaims2,777,321
24DCodes billed426
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Washington
Rank by total paid#5 of 49
Median peer was paid$20.06M
This provider vs. median3.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ROBERTSON, WILLIAM controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 243,171 | $6.40M | |
| 2019 | 307,263 | $8.64M | |
| 2020 | 353,869 | $9.60M | |
| 2021 | 453,929 | $11.96M | |
| 2022 | 493,447 | $14.71M | |
| 2023 | 491,241 | $14.04M | |
| 2024incomplete | 434,401 | $12.64M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 128,922 | 121,138 | $14.97M |
| 96361 | Intravenous infusion, hydration; each additional hour | 17% | 43,004 | 37,132 | $13.26M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.8% | 97,657 | 89,330 | $7.62M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.1% | 79,663 | 74,239 | $7.08M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.3% | 22,845 | 21,815 | $4.15M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.6% | 31,839 | 30,696 | $3.59M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 15,888 | 15,174 | $2.26M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.8% | 29,913 | 18,920 | $1.39M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.8% | 7,975 | 7,616 | $1.38M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 10,770 | 10,294 | $1.27M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 12,594 | 11,840 | $1.12M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.3% | 4,499 | 3,687 | $1.01M |
414 more codes
| 59025 | Fetal non-stress test | 1.2% | 6,909 | $965K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.2% | 1,916 | $897K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 5,386 | $847K |
| 12001 | <1% | 3,410 | $645K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 17,661 | $628K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,537 | $602K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 980 | $561K |
| 70496 | <1% | 3,162 | $547K | |
| 10060 | <1% | 3,033 | $545K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 20,173 | $505K |
| 80053 | Comprehensive metabolic panel | <1% | 118,149 | $460K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 21,492 | $446K |
| 12011 | <1% | 2,155 | $440K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 15,966 | $432K |
| J0475 | Injection, baclofen, 10 mg | <1% | 1,733 | $373K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,623 | $352K |
| 93971 | <1% | 4,186 | $351K | |
| 76830 | Ultrasound, transvaginal | <1% | 4,540 | $351K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,504 | $345K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,466 | $343K |
| 95800 | <1% | 1,395 | $342K | |
| 64493 | <1% | 670 | $336K | |
| 12002 | <1% | 1,584 | $286K | |
| 29125 | <1% | 2,030 | $247K | |
| 70491 | <1% | 1,637 | $243K | |
| 97130 | <1% | 1,535 | $215K | |
| 97127 | <1% | 730 | $210K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,273 | $201K |
| 95811 | <1% | 480 | $197K | |
| 84484 | <1% | 45,664 | $188K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 7,925 | $183K |
| 64635 | <1% | 469 | $176K | |
| 76801 | <1% | 4,861 | $176K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 691 | $176K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,072 | $158K |
| 29581 | <1% | 1,219 | $143K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 333 | $140K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 4,799 | $140K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,292 | $134K |
| 62369 | <1% | 1,705 | $122K | |
| 49083 | <1% | 304 | $114K | |
| 93970 | <1% | 1,140 | $107K | |
| 76770 | <1% | 1,074 | $101K | |
| G0378 | Hospital observation service, per hour | <1% | 13,211 | $98K |
| 83605 | <1% | 23,793 | $97K | |
| 76870 | <1% | 1,153 | $96K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 30,990 | $95K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 11,133 | $95K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,229 | $90K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 60,619 | $84K |
| 97597 | <1% | 1,828 | $82K | |
| 64400 | <1% | 292 | $81K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,804 | $80K |
| 70498 | <1% | 3,279 | $77K | |
| 95806 | <1% | 144 | $76K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 10,450 | $75K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,987 | $73K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 319 | $72K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,837 | $72K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,809 | $65K |
| 70486 | <1% | 2,215 | $63K | |
| 92609 | <1% | 1,460 | $62K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 2,199 | $61K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,069 | $61K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 444 | $59K |
| 97116 | <1% | 4,240 | $59K | |
| 97162 | <1% | 1,883 | $57K | |
| 83880 | <1% | 12,400 | $57K | |
| 87040 | <1% | 10,320 | $56K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,350 | $53K |
| 85379 | <1% | 12,886 | $51K | |
| 64494 | <1% | 739 | $51K | |
| 29515 | <1% | 548 | $51K | |
| 29848 | <1% | 37 | $50K | |
| 64483 | <1% | 112 | $50K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 74,874 | $48K |
| 70487 | <1% | 280 | $47K | |
| 52356 | <1% | 24 | $47K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,929 | $47K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 141 | $44K |
| 75574 | <1% | 214 | $43K | |
| 87400 | <1% | 4,480 | $42K | |
| 69209 | <1% | 414 | $41K | |
| 90715 | <1% | 2,289 | $41K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 33,643 | $41K |
| 90714 | <1% | 2,357 | $40K | |
| 87631 | <1% | 922 | $36K | |
| 93017 | <1% | 332 | $34K | |
| 47562 | <1% | 13 | $33K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 147,875 | $33K |
| 72131 | <1% | 996 | $33K | |
| 44970 | <1% | 12 | $31K | |
| 86756 | <1% | 5,244 | $30K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,020 | $28K |
| 97166 | <1% | 865 | $28K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 594 | $28K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 414 | $22K |
| 16020 | <1% | 228 | $22K | |
| 80143 | <1% | 6,310 | $22K | |
| 71045 | Radiologic examination, chest; single view | <1% | 25,283 | $22K |
| 97803 | <1% | 551 | $22K | |
| 0002A | <1% | 562 | $21K | |
| 87505 | <1% | 376 | $20K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,897 | $19K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 54,660 | $19K |
| 84145 | <1% | 2,078 | $19K | |
| 0001A | <1% | 659 | $19K | |
| 10061 | <1% | 137 | $18K | |
| 74175 | <1% | 94 | $16K | |
| 29105 | <1% | 285 | $15K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 25,261 | $15K |
| 82247 | <1% | 18,889 | $14K | |
| 71250 | <1% | 343 | $13K | |
| 36430 | <1% | 69 | $13K | |
| 97129 | <1% | 1,549 | $13K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 11,122 | $12K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 116 | $12K |
| J3490 | Unclassified drugs | <1% | 539 | $11K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,788 | $11K |
| 95819 | <1% | 52 | $11K | |
| 80179 | <1% | 6,182 | $11K | |
| 0012A | <1% | 293 | $11K | |
| 51702 | <1% | 983 | $10K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 39,179 | $10K |
| 88307 | <1% | 719 | $10K | |
| 80050 | General health panel | <1% | 1,791 | $10K |
| 73630 | <1% | 7,174 | $9K | |
| 74018 | <1% | 3,440 | $9K | |
| 95813 | <1% | 27 | $9K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 39,574 | $8K |
| 76937 | <1% | 225 | $8K | |
| 97802 | <1% | 112 | $8K | |
| 73130 | <1% | 6,223 | $8K | |
| 73610 | <1% | 6,740 | $8K | |
| 87420 | <1% | 564 | $8K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 48,880 | $7K |
| 36592 | <1% | 50,458 | $7K | |
| 73562 | <1% | 5,690 | $7K | |
| 74420 | <1% | 46 | $7K | |
| 85027 | <1% | 7,060 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,141 | $6K |
| 72193 | <1% | 38 | $6K | |
| 62323 | <1% | 12 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 26,600 | $6K |
| E0604 | Breast pump, hospital grade, electric (ac and / or dc), any type | <1% | 80 | $5K |
| 93798 | <1% | 887 | $5K | |
| 83735 | <1% | 9,624 | $5K | |
| 84703 | <1% | 20,352 | $5K | |
| 84702 | <1% | 14,567 | $5K | |
| 86140 | <1% | 23,792 | $5K | |
| 72128 | <1% | 234 | $5K | |
| 12013 | <1% | 37 | $5K | |
| 73701 | <1% | 27 | $5K | |
| 80061 | Lipid panel | <1% | 1,896 | $5K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,724 | $5K |
| 81025 | <1% | 27,908 | $5K | |
| 88304 | <1% | 1,956 | $5K | |
| 93797 | <1% | 975 | $4K | |
| 73030 | <1% | 5,001 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,004 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 17,584 | $4K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 50 | $4K |
| 72100 | <1% | 3,327 | $4K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 1,110 | $4K |
| 73110 | <1% | 4,724 | $4K | |
| 73700 | <1% | 65 | $4K | |
| 82803 | <1% | 20,142 | $4K | |
| 77001 | <1% | 68 | $4K | |
| 0011A | <1% | 153 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,550 | $4K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 118 | $4K |
| 81003 | <1% | 58,420 | $4K | |
| 81001 | <1% | 30,563 | $4K | |
| 76536 | <1% | 43 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 15,153 | $3K |
| 82962 | <1% | 12,746 | $3K | |
| 74230 | <1% | 57 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 19,919 | $3K |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 76 | $3K |
| 85610 | <1% | 26,360 | $3K | |
| 73502 | <1% | 2,446 | $3K | |
| 80051 | <1% | 20,443 | $3K | |
| 96376 | <1% | 18,059 | $3K | |
| 83690 | <1% | 19,618 | $3K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,239 | $3K |
| 96367 | <1% | 719 | $2K | |
| 87186 | <1% | 8,651 | $2K | |
| 82553 | <1% | 401 | $2K | |
| 73080 | <1% | 2,528 | $2K | |
| 82550 | <1% | 22,747 | $2K | |
| 73590 | <1% | 2,299 | $2K | |
| 90686 | <1% | 206 | $2K | |
| 88342 | <1% | 570 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12,291 | $2K |
| 64636 | <1% | 452 | $2K | |
| 97167 | <1% | 45 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 13,085 | $2K |
| 85652 | <1% | 3,226 | $2K | |
| 74022 | <1% | 746 | $2K | |
| 97165 | <1% | 44 | $2K | |
| 86901 | <1% | 5,769 | $2K | |
| 72040 | <1% | 1,061 | $2K | |
| 82077 | <1% | 9,451 | $2K | |
| 82248 | <1% | 662 | $2K | |
| 86900 | <1% | 5,148 | $2K | |
| 99152 | <1% | 4,609 | $2K | |
| 86780 | <1% | 874 | $2K | |
| 92523 | <1% | 13 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 3,802 | $2K |
| 82075 | <1% | 2,528 | $2K | |
| 73090 | <1% | 2,279 | $2K | |
| 73140 | <1% | 2,550 | $2K | |
| 82565 | <1% | 20,674 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 302 | $2K |
| 82150 | <1% | 17,567 | $2K | |
| 86850 | <1% | 3,776 | $2K | |
| 82977 | <1% | 17,537 | $1K | |
| 85014 | <1% | 1,978 | $1K | |
| A4649 | Surgical supply; miscellaneous | <1% | 3,097 | $1K |
| 86923 | <1% | 168 | $1K | |
| 81002 | <1% | 2,475 | $1K | |
| 87070 | <1% | 9,043 | $1K | |
| 84100 | <1% | 1,836 | $1K | |
| 80305 | <1% | 7,208 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 11,096 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13,608 | $1K |
| 73560 | <1% | 596 | $1K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 32 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 6,652 | $1K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,201 | $1K |
| 97542 | <1% | 54 | $1K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 4,588 | $990.64 |
| 87808 | <1% | 3,062 | $978.85 | |
| 51798 | <1% | 606 | $965.58 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13,625 | $921.03 |
| 82947 | <1% | 20,739 | $917.53 | |
| 80076 | <1% | 475 | $888.33 | |
| 87481 | <1% | 4,449 | $878.82 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,829 | $871.59 |
| 87205 | <1% | 7,425 | $866.11 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 61 | $827.60 |
| 84075 | <1% | 17,374 | $826.84 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 15,467 | $810.52 |
| 84450 | <1% | 17,422 | $806.53 | |
| 90674 | <1% | 75 | $802.22 | |
| 84460 | <1% | 17,421 | $800.59 | |
| 84439 | <1% | 825 | $798.70 | |
| 82040 | <1% | 17,456 | $784.11 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 6,301 | $775.34 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 2,353 | $766.31 |
| 36416 | <1% | 10,499 | $763.57 | |
| 84520 | <1% | 20,646 | $762.74 | |
| 73660 | <1% | 425 | $708.20 | |
| J2704 | Injection, propofol, 10 mg | <1% | 11,902 | $700.61 |
| 99153 | Mod sedat endo service >5yrs | <1% | 2,200 | $691.42 |
| 71101 | <1% | 1,500 | $690.65 | |
| 73552 | <1% | 357 | $688.43 | |
| 84155 | <1% | 17,431 | $666.12 | |
| 92611 | <1% | 29 | $627.03 | |
| C1729 | Catheter, drainage | <1% | 1,518 | $609.20 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 15,338 | $584.52 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 117 | $572.15 |
| 87641 | <1% | 86 | $560.02 | |
| 97161 | <1% | 13 | $541.99 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 1,222 | $532.01 |
| 82570 | <1% | 690 | $523.98 | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 13 | $510.49 |
| 85018 | <1% | 1,014 | $493.69 | |
| 87430 | <1% | 1,727 | $492.96 | |
| 82728 | <1% | 257 | $481.52 | |
| 87088 | <1% | 3,541 | $434.79 | |
| 85730 | <1% | 3,721 | $432.02 | |
| 72170 | <1% | 455 | $401.44 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,065 | $363.75 |
| 72220 | <1% | 12 | $356.55 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 821 | $356.34 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,522 | $339.46 |
| 80074 | <1% | 313 | $325.88 | |
| 92610 | <1% | 12 | $319.06 | |
| 96368 | <1% | 442 | $315.63 | |
| 97760 | <1% | 15 | $313.20 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 3,552 | $303.60 |
| 86308 | <1% | 1,515 | $287.08 | |
| 84132 | <1% | 695 | $281.24 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 164 | $271.76 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,810 | $265.50 |
| 88142 | <1% | 17 | $261.59 | |
| 82010 | <1% | 1,818 | $248.86 | |
| 84156 | <1% | 536 | $244.72 | |
| 87077 | <1% | 2,153 | $234.44 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 7,070 | $227.27 |
| 73060 | <1% | 466 | $217.19 | |
| C1769 | Guide wire | <1% | 2,551 | $209.35 |
| 87529 | <1% | 41 | $198.13 | |
| 72070 | <1% | 122 | $190.60 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,157 | $187.28 |
| 82607 | <1% | 114 | $184.31 | |
| 83550 | <1% | 155 | $179.33 | |
| 87149 | <1% | 406 | $177.05 | |
| 83540 | <1% | 208 | $173.98 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 10,226 | $172.80 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 2,842 | $161.13 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 438 | $159.30 |
| 82731 | <1% | 15 | $148.67 | |
| 84550 | <1% | 473 | $138.34 | |
| 85007 | <1% | 1,033 | $133.82 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 286 | $130.10 |
| J1815 | Injection, insulin, per 5 units | <1% | 4,780 | $106.95 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,944 | $104.22 |
| 70360 | <1% | 42 | $97.54 | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 146 | $93.54 |
| 73070 | <1% | 84 | $85.59 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 24 | $84.77 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 326 | $81.03 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,310 | $79.75 |
| 82270 | <1% | 958 | $77.03 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 34 | $75.67 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 251 | $74.38 |
| 72072 | <1% | 39 | $69.82 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,276 | $69.06 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 452 | $65.23 |
| 85049 | <1% | 27 | $64.51 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,734 | $64.39 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 573 | $54.99 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 617 | $45.91 |
| 87510 | <1% | 14 | $44.40 | |
| 87660 | <1% | 14 | $44.40 | |
| 73000 | <1% | 43 | $43.24 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 241 | $37.99 |
| 87493 | <1% | 129 | $37.85 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 1,365 | $35.51 |
| 94761 | <1% | 1,080 | $34.25 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 557 | $33.84 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 686 | $33.62 |
| 86803 | <1% | 82 | $31.50 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 241 | $31.19 |
| 82140 | <1% | 41 | $26.13 | |
| 84295 | <1% | 113 | $20.89 | |
| 82330 | <1% | 45 | $20.22 | |
| 87806 | <1% | 454 | $19.04 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 399 | $18.09 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 306 | $15.02 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,169 | $13.96 |
| 82746 | <1% | 26 | $12.86 | |
| 83615 | <1% | 73 | $11.86 | |
| 82365 | <1% | 13 | $9.14 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 619 | $8.95 |
| 82805 | <1% | 61 | $8.68 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 795 | $7.34 |
| 87449 | <1% | 13 | $7.32 | |
| 87209 | <1% | 16 | $7.24 | |
| 87184 | <1% | 113 | $7.22 | |
| 87081 | <1% | 30 | $6.76 | |
| 87045 | <1% | 14 | $6.72 | |
| A4314 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | <1% | 273 | $6.01 |
| 87427 | <1% | 14 | $3.66 | |
| 87177 | <1% | 16 | $3.62 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 613 | $3.61 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 449 | $3.43 |
| 89051 | <1% | 339 | $2.50 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 132 | $1.18 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 200 | $1.14 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,511 | $0.94 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 721 | $0.83 |
| 94760 | <1% | 138 | $0.70 | |
| A4351 | Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each | <1% | 667 | $0.33 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 378 | $0.28 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 77 | $0.28 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 260 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 64 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 232 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 626 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 113 | $0.00 |
| 87480 | 0% | 14 | $0.00 | |
| J1836 | Injection, metronidazole, 10 mg | 0% | 310 | $0.00 |
| 91301 | 0% | 459 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 597 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 15 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 55 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 44 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 29 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 68 | $0.00 |
| A4338 | Indwelling catheter; foley type, two-way latex with coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each | 0% | 53 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 64 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 20 | $0.00 |
| 64484 | 0% | 12 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 27 | $0.00 |
| 87340 | 0% | 33 | $0.00 | |
| 82435 | 0% | 14 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 12 | $0.00 |
| 86706 | 0% | 13 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 109 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 22,234 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 215 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 184 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 92 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 180 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 89 | $0.00 |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | 0% | 36 | $0.00 |
| 87210 | 0% | 29 | $0.00 | |
| 91300 | 0% | 1,184 | $0.00 | |
| G0390 | Trauma response team associated with hospital critical care service | 0% | 24 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 343 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 77 | $0.00 |
| 0225U | 0% | 25 | $0.00 | |
| A4565 | Slings | 0% | 12 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 40 | $0.00 |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | 0% | 17 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 32 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 13 | $0.00 |
| 88112 | 0% | 14 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 13 | $0.00 |
| C2625 | Stent, non-coronary, temporary, with delivery system | 0% | 14 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 100 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROBERTSON, WILLIAM (CEO)
| Provider | Location | Paid |
|---|---|---|
| Multicare Health System | Tacoma, WA | $162.25M |
| Multicare Health System | Tacoma, WA | $108.54M |
| Yakima Valley Memorial Hospital Association | Yakima, WA | $103.54M |
| Multicare Health System | Tacoma, WA | $75.17M |
| Greater Lakes Mental Health Foundation INC | Lakewood, WA | $55.95M |
| Multicare Health System | Spokane, WA | $55.23M |
| Multicare Health System | Auburn, WA | $31.02M |
| Multicare Health System | Spokane Valley, WA | $24.75M |
| Multicare Health System | Covington, WA | $23.19M |
| Multicare Health System | Olympia, WA | $16.97M |
| Multicare Health System | Tacoma, WA | $11.14M |
| Multicare Health System | Auburn, WA | $7.42M |
| Multicare Health System | Tacoma, WA | $2.68M |
| Alliance for South Sound Health | Tacoma, WA | $2.46M |
| Capital Medical Center Physicians LLC | Olympia, WA | $1.75M |
| Multicare Health System | Tacoma, WA | $1.53M |
| Yakima Valley Memorial Hospital Association | Yakima, WA | $1.16M |
| Capital Medical Center Specialty Physicians, LLC | Olympia, WA | $987K |
| Yakima Urology at Memorial TR | Yakima, WA | $784K |
| Multicare Health System | Spokane, WA | $179K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.